This Article Full Text (PDF) All Versions of this Article: 1756285609104792v1 2/4/261    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Lehmann, H. C. Articles by Hartung, H.-P. Social Bookmarking                         What's this?

Review: Pathogenesis and treatment of immune-mediated neuropathies

Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany hans-peter.hartung@ uni-duesseldorf.de

Gerd Meyer zu Horste

Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany

Bernd C. Kieseier

Department of Neurology, Johns Hopkins Hospital, Baltimore, USA

Hans-Peter Hartung

Department of Neurology, HeinrichHeine-University, Düsseldorf, Germany

Immune-mediated neuropathies represent a heterogeneous spectrum of peripheral nerve disorders that can be classified according to time course, predominant involvement of motor/sensory fibers, distribution of deficits and paraclinical parameters such as electrophysiology and serum antibodies. In the last few years, significant advances have been achieved in elucidating underlying pathomechanisms, which made it possible to identify potential therapeutic targets. In this review, we discuss the latest development in pathogenesis and treatment of immune-mediated neuropathies.

Key Words: immune neuropathies • Guíllan-Barré syndrome • cidp • paraproteinemic neuropathies • treatments

This version was published on July 1, 2009

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 4, 261-281 (2009)
DOI: 10.1177/1756285609104792


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?